Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Daily

Download Data

Icosavax Inc Market Capitalization on February 29, 2024

Icosavax Inc Market Capitalization is NA on February 29, 2024, a NA change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Icosavax Inc 52-week high Market Capitalization is USD 795.43 M on January 02, 2024, which is NA below the current Market Capitalization.
Icosavax Inc 52-week low Market Capitalization is USD 219.19 M on April 20, 2023, which is NA below the current Market Capitalization.
Icosavax Inc average Market Capitalization for the last 52 weeks is USD 451.86 M.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends